Company: ADPT
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103752
Chunk: 35

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 35
---
 Target PSUs. Mr. Piskel’s variance to 2023 units awarded was excluded since he was not the Chief Financial Officer in 2023. |

Although the peer group benchmarking data would have historically supported higher compensation for Mr. Robins, he has recommended to the compensation and human capital committee since 2020 that he not receive an actual equity grant value greater than the equity grant value awarded to Dr. Robins. The compensation and human capital committee, having already determined market-competitive individual target equity values for each executive using the market comparisons described above, elected to average the individually-calibrated target equity values to ensure a “zero-sum”process between actual grants to the co-foundersand their role-based target equity values. The compensation and human capital committee believes that this process recognizes the criticality of each of our co-foundersto our success and the expansive scope of our co-founders’roles. Similar to 2024, in an effort to manage potential dilution to shareholders, the compensation and human capital committee continued to generally hold flat the number of aggregate shares granted to the executive team, which includes our named executive officers, in 2025. While the aggregate number of shares was held relatively flat year-over-year, the individual allocation of shares varied slightly year-over-year based on competitiveness to market, tenure and performance in role, and other factors

| Name                 |     | Total   
 2024    
 Target  
 Units   
 Granted |           |     | Total   
 2025    
 Target  
 Units   
 Granted |           |     | % Variance to Total 
 2024 Target Units   
 Granted             |   |   |
| Chad Robins          |     |         |   709,220 |     |         |   710,000 |     |                     | — |   |
| Rest of 2024 NEOs(1) |     |         | 1,541,748 |     |         | 1,585,000 |     |                     | 3 | % |

| (1) | Excludes Mr. Peterson as his employment ended in April 2024. |

Compensation Program The compensation and human capital committee annually assesses the effectiveness of our executive compensation program and reviews risk mitigation and governance matters. The compensation and human capital committee, during its first meeting of the year, addresses achievement of the prior year’s corporate goals for purposes of determining annual cash incentives. Most of the significant adjustments to compensation elements are also made in the first meeting of the year. Specific issues considered with